OOIR: Observatory of International Research

Papers

(The TQCC of Lancet Haematology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Towards reparatory measures: blood donation, health systems, and men who have sex with men	320
In the trenches	250
Zanubrutinib-associated ecchymotic lesions	198
Prioritising health equity alongside donation safety – Authors' reply	169
Correction to Lancet Haematol 2023; 10: e333–45	167
Correction to Lancet Haematol 2023; published online Aug 28. https://doi.org/10.1016/S2352-3026(23)00164-3	141
Correction to Lancet Haematol 2024; 11: e114–26	139
Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?	116
Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma?	116
Optimising communication to patients with venous thromboembolism: development of a provider toolkit	115
Vaccine efficacy and iron deficiency: an intertwined pair?	114
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries	109
Managing haematological malignancies in pregnant women	104
Retinal haemorrhage as a complication of blastic plasmacytoid dendritic cell neoplasm	94
MRD-guided treatment cessation in multiple myeloma	89
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial	88
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts	85
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?	85
International Society on Thrombosis and Haemostasis Congress 2023	81
Be compliant or compromise?	79
Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia	72
The HemeOncBuddy app—a new tool to keep up with the clinical trial storm	71
Bedside art is good medicine	70
Artwork from trauma: the social life of medical data	68
CAR T cells in CNS-relapsed leukaemia: one step forward	68

Methodological challenges in the development of endpoints for myelofibrosis clinical trials	67
Rituximab versus active surveillance in patients with follicular lymphoma	67
Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia	67
Racial and ethnic survival disparities in patients with haematological malignancies in the USA: time to stop ignoring the numbers	66
Correction to Lancet Haematol 2025; 12: e294–303	65
Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial	64
Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations	61
Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study	61
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, ran	60
Blood deserts: a vision to tackle blood inaccessibility	59
Living with sickle cell disease: voices from sub-Saharan Africa	58
Blood cell defence against pathogens	58
Call to action: equitable comprehensive care for patients with sickle cell disease in the USA	57
Correction to Lancet Haematol 2023; 10: e433–44	57
Eltrombopag–cyclosporin A in treating severe aplastic anaemia	56
Production and supply of blood products in Brazil	54
Sickle cell disease in India: current status and progress	53
Update on SickleInAfrica: a collaborative and multidimensional approach to conduct research and improve health	53
25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial	52
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study	51
USAID's enduring impact on anaemia management must be preserved	50
Anaemia in a time of climate crisis	50
Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study	50
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past	50
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study	49
Idiopathic multicentric Castleman disease with arteriolar endotheliopathy and secondary haemophagocytosis	49
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective	49
Universal health coverage for children with cancer	48
Could improving mental health disorders help increase cancer survival?	48
Correction to Lancet Haematol 2022; Published online July 27. https://doi.org/10.1016/S2352-3026(22)00206-X	47
Progressive multifocal leukoencephalopathy in the era of chimeric antigen receptor T-cell therapy	47
Correction to Lancet Haematol 2022; 9: e200–07	46
Correction to Lancet Haematol 2024; 11: e310–11	46
Oreofe Odejide—aiming to raise the bar in haematology care	46
Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war	45
Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial	44
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment	44
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial	43
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial	43
Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond	42
CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials	41
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study	41
A long-awaited benchmark in lymphomatoid granulomatosis	41
Beyond maximum grade: advancing the measurement and analysis of adverse events in malignant haematology trials in the modern era	41
Addressing inequity in access to palliative care for patients with non-malignant or benign haematological diseases	41
[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial	41
Thank you to our 2022 peer reviewers and an update on inclusion and diversity	38
Sickle cell disease—unity and patient-centred education	38
The rollercoaster of vaccine-induced immune thrombotic thrombocytopenia	37
Secondary haematological malignancies	37

Lakshmi Nayak: striving to contain the brain's deadliest killers	37
Haemophilia—unparalleled progress but inadequate access	36
Elotuzumab: no additional effect in patients with newly diagnosed multiple myeloma	36
Striking the right balance	36
Reporting of trials with possible detrimental overall survival: a patient advocate perspective	36
Should patients with haemophilia receive gene therapy?	36
Haematology and climate change	36
The challenge of defining the global burden of iron deficiency anaemia	34
Correction to Lancet Haematol 2024; 11: e521–29	33
Efficacy or convenience? Subcutaneous blinatumomab as a promising new treatment for B-cell acute lymphoblastic leukaemia	33
Patients first: improving toxicity assessment and reporting	32
2024 ASH Annual Meeting	32
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study	32
In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospecti	31
Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation	31
Comparison of international guideline recommendations for the diagnosis of pulmonary embolism	31
Carfilzomib–lenalidomide–dexamethasone versus lenalidomide–dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label,	30
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management	30
Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial	29
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-lab	29
Can defibrotide prophylaxis prevent sinusoidal obstruction syndrome following haematopoietic stem-cell transplantation?	28
Removing unfair barriers to blood donation	28
Life beyond blood disorders	27
In defence of individualised medicine	27
Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?	26
Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 t	26
Thank you to The Lancet Haematology's peer reviewers in 2022	26
The case for equitable haemophilia care	26
Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma	26
The Lancet Haematology at 10	26
Sovleplenib in immune thrombocytopenia	26
Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting Series	25
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group	25
Breaking sex biases: access for all in haemophilia care	25
The impact of patient ethnicity on haematopoietic cell transplantation outcome: a retrospective cohort study on the UK experience	25
Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care	25
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study	25
Management of pregnancies with anti-K alloantibodies and the predictive value of anti-K titration testing	25
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7)	23
Gene therapy in China: past, present, and future	23
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow	23
Melflufen in multiple myeloma: the conclusion matters	22
A rare blood disorder that created a watercolour storytelling movement	22
A treatise on clinical trials	22
Acquired haemophilia in an Edo period Japanese surgical casebook	22
Artificial intelligence in peripheral blood films: an evolving landscape	22
Needles were the least of my worries	21
Heavy menstrual blood loss in patients with von Willebrand disease: an unsolved problem	21
Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study	21
Monumen-TAL progress in the treatment of relapsed multiple myeloma	21
The effects of upward revision of haemoglobin thresholds for anaemia in blood donations	21
Ask, do not tell: consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe	21
Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial	21
Clinical trial design change implementation for inclusive studies	21
Don Thomas: leading the charge to bone marrow transplantation	21
Experience of the Anaemia Mukt Bharat anaemia control programme in India	20
Making a case for disease-modifying agents in myelofibrosis	20
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study	20
Virtual twins for personalised CAR T-cell therapy in myeloma	20
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation t	20
Patients receiving allogeneic haematopoietic stem-cell transplantation and clinical outcomes after early access to palliative care	20
Iron deficiency anaemia in sub-Saharan Africa: a review of current evidence and primary care recommendations for high-risk groups	20
Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia	19
Oleksandr Lysytsia: the war in Ukraine has changed everything about our lives	19
COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria	19
Incidence and prognosis of superficial vein thrombosis during pregnancy and the post-partum period: a Danish nationwide cohort study	18
Epistemic limitations of measurable residual disease in haematological malignancies	18
Reducing toxic waste: improving toxicity capture in childhood cancer	18
Improved survival and enhanced quality of life through anaemia correction in lower risk myelodysplastic syndromes: meaningful insights from an EUMDS Registry study	18
Mitapivat for treatment of pyruvate kinase deficiency	18
Lines of the haematology community	18
Antifibrinolytics do not add to the benefits of platelet transfusion	18
Making blood count	18
Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial	17
Correction to Lancet Haematol 2025; 12: e562–63	16
A comprehensive approach to therapy of haematological malignancies in older patients	16
Immunochemotherapy for life-threatening haematological malignancies in pregnancy: a systematic review of the literature and cross-sectional analysis of clinical trial eligibility	16
Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial	16
Low-dose dasatinib: when less can be more	16
Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China	16

Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, sing	16
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study	15
Haematological malignancies in sub-Saharan Africa: east Africa as an example for improving care	15
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study	14
Long term strategies for individuals with sickle cell disease	14
Time to define and refine maintenance strategies in acute myeloid leukaemia	14
The effects of revised haemoglobin cutoffs on the global burden of anaemia	14
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose e	14
Lallindra Gooneratne—maintaining treatment flow amid crisis	14
Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial	14
Correction to Lancet Haematol 2021; 8: e55–66	14
Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa	14
An integrated approach to cardioprotection in lymphomas	13
Correction to Lancet Haematol 2023; 10: e203–12	13
Reactivating hope for TP53-mutated acute myeloid leukaemia?	13
Sexually transmitted infections in the context of haematological malignancies	13
Melflufen in multiple myeloma: the conclusion matters – Authors' reply	13
Iron deficiency anaemia—an ongoing challenge	13
Conditioning regimens for HSCT for patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukaemia	13
Correction to Lancet Haematol 2024; 11: e862–72	13
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the U	12
Follicular lymphoma: is more better or is less really more?	12
Haemoglobin thresholds to define anaemia from age 6 months to 65 years: estimates from international data sources	12
The value of anti-CD30 CAR T cells in Hodgkin lymphoma	12
Public health and programme development in sickle cell disease in Ghana: the legacy of Kwaku Ohene-Frempong	12
Haematology in sub-Saharan Africa: advances and opportunities in health care, education, and research	12
Treatment approaches for patients with TP53-mutated mantle cell lymphoma	12
Under-recognition of measurement and management of serum ferritin among populations at high risk of iron deficiency – Authors' reply	11
Prehospital blood transfusion for haemorrhagic shock – Authors' reply	11
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?	11
Oncology service priorities for the new UK Government	11
Correction to Lancet Haematol 2023; 10: e713–34	11
Virginia Abello Polo—a once-in-a-lifetime opportunity	11
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?	11
Isolated IgG4-related disease of the left maxillary antrum	11
Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?	11
Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice	11
Concerns on perioperative anaemia management in the FIT trial	11
Renal colocalisation of Rosai-Dorfman-Destombes disease and secondary AA amyloidosis successfully treated with lenalidomide and dexamethasone	10
Under-recognition of measurement and management of serum ferritin among populations at high risk of iron deficiency	10
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial	10
Inequalities in the career pathway for paediatric HSCT and cellular therapy physicians	10
CAR T-cell therapies in China: rapid evolution and a bright future	10
Fitusiran prophylaxis in severe haemophilia without inhibitors	10
Mental health and psychological resilience in sickle cell disease	9
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study	9
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomise	9
Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome	9
Correction to Lancet Haematol 2025; 12: e128–37	9
Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study	9
Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial	9
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study	9
Safe blood supply in sub-Saharan Africa: challenges and opportunities	9
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study	9
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial	9